EIF2AK3 and neoplasm: This study investigated EIF2AK3/PERK expression across 28 tumour types (n = 7,251) and their matched normal adjacent tissues (NATs; n = 667) from the Cancer Genome Atlas (TCGA) database, along with additional normal tissue samples from the Genotype-Tissue Expression (GTEx) project (n = 1,736), and 1,179 tumour cell lines, examining correlations with patient demographics, tumour stage, survival and genetic alterations.